Biomarkers of drug-induced liver injury

References

• Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opin DrugMetab Toxicol. 2009;5(5):463–473.
   PubMed Web of Science ®Google Scholar
• Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007;6(6):673–684.
   PubMed Web of Science ®Google Scholar
• Shi Q, Hong H, Senior J, Tong W. Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol. 2010;4(2):225–234.
   PubMed Web of Science ®Google Scholar
• Rangnekar AS, Fontana RJ. An update on drug induced liver injury. Minerva Gastroenterol Dietol. 2011;57(2):213–229.
   Google Scholar
• Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–455.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet. 2011;26(1):3–14.
   PubMed Web of Science ®Google Scholar
• Lee WM. Acute liver failure. Semin Respir Crit Care Med. 2012;33(1):36–45.
   PubMed Web of Science ®Google Scholar
• Hadem J, Tacke F, Bruns T, et al. Etiologies and outcomes of acute liver failure in Germany. Clin Gastroenterol Hepatol. 2012;10(6):664–669, e662.
   PubMed Web of Science ®Google Scholar
• Bell LN, Vuppalanchi R, Watkins PB, et al. Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2012;35(5):600–612.
   PubMed Web of Science ®Google Scholar
• Van Summeren A, Renes J, van Delft JH, Kleinjans JC, Mariman EC. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. Toxicol In Vitro. 2012;26(3):373–385.
   PubMed Web of Science ®Google Scholar
• Mendrick DL. Transcriptional profiling to identify biomarkers of disease and drug response. Pharmacogenomics. 2011;12(2):235–249.
   PubMed Web of Science ®Google Scholar
• Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8(5):463–470.
   PubMed Web of Science ®Google Scholar
• Nelson SD. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis. 1990;10(4):267–278.
   PubMed Web of Science ®Google Scholar
• Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol. 2011;8(4):202–211.
   PubMed Web of Science ®Google Scholar
• McBurney RN, Hines WM, Von Tungeln LS, et al. The liver toxicity biomarker study: phase I design and preliminary results. Toxicol Pathol. 2009;37(1):52–64.
   Web of Science ®Google Scholar
• Long JP, Fitzgerald O, Maurer BJ. Hepatotoxicity following treatment with perhexiline maleate. Ir Med J. 1980;73(7):275–276.
   Google Scholar
• Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev. 2007;25(1):76–97.
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis. 2009;29(4):383–392.
   PubMed Web of Science ®Google Scholar
• Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev. 2012;44(1):88–106.
   PubMed Web of Science ®Google Scholar
• Ju C, Reilly T. Role of immune reactions in drug-induced liver injury (DILI). Drug Metab Rev. 2012;44(1):107–115.
   PubMed Web of Science ®Google Scholar
• Njoku DB. Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review. Expert Opin Drug Metab Toxicol. 2010;6(5):519–531.
   PubMed Web of Science ®Google Scholar
• Holt M, Ju C. Drug-induced liver injury. Handb Exp Pharmacol. 2010;196:3–27.
   Google Scholar
• Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J. 2006;8(1):E48–E54.
   Web of Science ®Google Scholar
• Pollak PT, Sharma AD, Carruthers SG. Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. Am J Cardiol. 1990;65(18):1185–1191.
   Web of Science ®Google Scholar
• Huang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2007;3(1):1–8.
   PubMed Web of Science ®Google Scholar
• Behl M, Nyska A, Chhabra RS, et al. Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to kava kava. Food Chem Toxicol 2011;49(11):2820–2829.
   PubMed Web of Science ®Google Scholar
• Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr. 2011;53(2):182–189.
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004; 38 Suppl 2:S44–S48.
   Google Scholar
• Grattagliano I, Bonfrate L, Diogo CV, Wang HH, Wang DQ, Portincasa P. Biochemical mechanisms in drug-induced liver injury: certainties and doubts. World J Gastroenterol. 2009;15(39):4865–4876.
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009;62(6):481–492.
   PubMed Web of Science ®Google Scholar
• Strazzabosco M, Fabris L, Spirli C. Pathophysiology of cholangiopathies. J Clin Gastroenterol. 2005;39(4 Suppl 2):S90–S102.
   Web of Science ®Google Scholar
• Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011;9(6):517–523, e513.
   PubMed Web of Science ®Google Scholar
• Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6(3):755–774.
   PubMedGoogle Scholar
• Velayudham LS, Farrell GC. Drug-induced cholestasis. Expert Opin Drug Saf. 2003;2(3):287–304.
   PubMedGoogle Scholar
• Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated cholestatic hepatitis. Med JAust. 1993;158(9):600–602.
   Google Scholar
• Schreiber AJ, Simon FR. Estrogen-induced cholestasis: clues to pathogenesis and treatment. Hepatology. 1983;3(4):607–613.
   Web of Science ®Google Scholar
• Parker WA, Shearer CA. Phenytoin hepatotoxicity: a case report and review. Neurology. 1979;29(2):175–178.
   Web of Science ®Google Scholar
• Di Mizio G, Gambardella A, Labate A, Perna A, Ricci P, Quattrone A. Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients. Seizure. 2007;16(7):653–656.
   Web of Science ®Google Scholar
• Burgunder JM, Abernethy DR, Lauterburg BH. Liver injury due to verapamil. Hepatogastroenterology. 1988;35(4):169–170.
   Google Scholar
• Rubin E. Iatrogenic hepatic injury. Hum Pathol. 1980;11(4):312–331.
   Web of Science ®Google Scholar
• Pachkoria K, Lucena MI, Molokhia M, et al. Genetic and molecular factors in drug-induced liver injury: a review. Curr Drug Saf. 2007;2(2):97–112.
   Google Scholar
• Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics. 2009;10(9):1467–1487.
   PubMed Web of Science ®Google Scholar
• Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev. 2012;44(1):116–126.
   PubMed Web of Science ®Google Scholar
• Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug- induced liver injury. Hepatology. 2010;52(2):748–761.
   PubMed Web of Science ®Google Scholar
• Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics. 2010;11(5):607–611.
   PubMed Web of Science ®Google Scholar
• Laverty HG, Antoine DJ, Benson C, Chaponda M, Williams D, Kevin Park B. The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol. 2010;66(10):961–976.
   PubMed Web of Science ®Google Scholar
• Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816–819.
   PubMed Web of Science ®Google Scholar
• Zhang M, Chen M, Tong W. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans? Chem Res Toxicol. 2012;25(1):122–129.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M. Genetics and the potential for predictive tests in adverse drug reactions. Chem Immunol Allergy. 2012;97:18–31.
   Google Scholar
• Zhang YN, Cui W, Han M, et al. Gene polymorphism of CYP450 2C9 and VKORC1 in Chinese population and their relationships to the maintaining dosage of warfarin. Zhonghua Liu Xing Bing Xue Za Zhi. 2010;31(2):218–222. Chinese.
   Google Scholar
• Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature. 2003;424(6947):464–468.
   PubMed Web of Science ®Google Scholar
• Higuchi N, Tahara N, Yanagihara K, et al. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol. 2007;13(45):6003–6008.
   PubMed Web of Science ®Google Scholar
• Wang K, Lee I, Carlson G, Hood L, Galas D. Systems biology and the discovery of diagnostic biomarkers. Dis Markers. 2010;28(4):199–207.
   PubMed Web of Science ®Google Scholar
• Soga T, Baran R, Suematsu M, et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem. 2006;281(24):16768–16776.
   PubMed Web of Science ®Google Scholar
• Lee MS, Jung BH, Chung BC, et al. Metabolomics study with gas chromatography-mass spectrometry for predicting valproic acid-induced hepatotoxicity and discovery of novel biomarkers in rat urine. Int J Toxicol. 2009;28(5):392–404.
   PubMed Web of Science ®Google Scholar
• Young TH, Tang HS, Chao YC, et al. Quantitative rat liver function test by galactose single point method. Lab Anim. 2008;42(4):495–504.
   Google Scholar
• Beger RD, Sun J, Schnackenberg LK. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol Appl Pharmacol. 2010;243(2):154–166.
   PubMed Web of Science ®Google Scholar
• Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008;245(3):194–205.
   PubMed Web of Science ®Google Scholar
• Nissen NI, Ranlov P, Weis-Fogh J. Evaluation of four different serum enzymes in the diagnosis of acute myocardial infarction. Br Heart J. 1965;27:520–526.
   Google Scholar
• Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem. 2000;46(12):2027–2049.
   PubMed Web of Science ®Google Scholar
• Volkmann X, Anstaett M, Hadem J, et al. Caspase activation is associated with spontaneous recovery from acute liver failure. Hepatology. 2008;47(5):1624–1633.
   Web of Science ®Google Scholar
• McGill MR, Sharpe MR, Williams CD, Taha M, Curry SC, Jaeschke H. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest. 2012;122(4):1574–1583.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Jenkins RE, Dear JW, et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol. 2012;56(5):1070–1079.
   PubMed Web of Science ®Google Scholar
• Rutherford A, King LY, Hynan LS, et al. Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology. 2012;143(5):1237–1243.
   Web of Science ®Google Scholar
• Reuben A. Hy’s law. Hepatology. 2004;39(2):574–578.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Yanai M, Ookubo S, Awasaki N, Takami K, Imai R. Detection of cell-free, liver-specific mRNAs in peripheral blood from rats with hepatotoxicity: a potential toxicological biomarker for safety evaluation. Toxicol Sci. 2008;106(2):538–545.
   Web of Science ®Google Scholar
• Wetmore BA, Brees DJ, Singh R, et al. Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury. Hepatology. 2010;51(6):2127–2139.
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009;106(11):4402–4407.
   PubMed Web of Science ®Google Scholar
• Yokoi T, Nakajima M. Toxicological implications of modulation of gene expression by microRNAs. Toxicol Sci. 2011;123(1):1–14.
   PubMed Web of Science ®Google Scholar
• Starkey Lewis PJ, Dear J, Platt V et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 2011;54(5):1767–1776.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jia Y, Zheng R, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem. 2010;56(12):1830–1838.
   PubMed Web of Science ®Google Scholar
• Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol. 2011;7(7):875–890.
   PubMed Web of Science ®Google Scholar
• Perez Alea M, Kitamura M, Martin G, Thomas V Hitomi K, El Alaoui S. Development of an isoenzyme-specific colorimetric assay for tissue transglutaminase 2 cross-linking activity. Anal Biochem. 2009;389(2):150–156.
   Web of Science ®Google Scholar
• James LP, Letzig L, Simpson PM, et al. Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab Dispos. 2009;37(8):1779–1784.
   PubMed Web of Science ®Google Scholar
• Qin S, Zhou Y, Lok AS, et al. SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics. 2012;12(8):1244–1252.
   PubMed Web of Science ®Google Scholar
• Chladek J, Simkova M, Vaneckova J, Hroch M, Vavrova J, Hulek P. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers. J Eur Acad Dermatol Venereol August 7, 2012. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today. 2011;16(15–16):697–703.
   PubMed Web of Science ®Google Scholar
• Surinova S, Schiess R, Huttenhain R, Cerciello F, Wollscheid B, Aebersold R. On the development of plasma protein biomarkers. J Proteome Res. 2011;10(1):5–16.
   PubMed Web of Science ®Google Scholar
• Evans C, Noirel J, Ow SY, et al. An insight into iTRAQ: where do we stand now? Anal Bioanal Chem. 2012;404(4):1011–1027.
   PubMed Web of Science ®Google Scholar
• Cappadona S, Baker PR, Cutillas PR, Heck AJ, van Breukelen B. Current challenges in software solutions for mass spectrometry-based quantitative proteomics. Amino Acids. 2012;43(3):1087–1108.
   PubMed Web of Science ®Google Scholar
• Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/ MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012;11(6):0111.016717.
   Web of Science ®Google Scholar
• Berglund L, Bjorling E, Oksvold P, et al. A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics. 2008;7(10):2019–2027.
   PubMed Web of Science ®Google Scholar
• Shi T, Su D, Liu T, et al. Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics. Proteomics. 2012;12(8):1074–1092.
   PubMed Web of Science ®Google Scholar
• Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods. 2012;9(6):555–566.
   PubMed Web of Science ®Google Scholar
• Woodhead JL, Howell BA, Yang Y, et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug- induced liver injury. J Pharmacol Exp Ther. 2012;342(2):529–540.
   PubMed Web of Science ®Google Scholar
• Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1(11):845–867.
   PubMed Web of Science ®Google Scholar
• Apweiler R, Aslanidis C, Deufel T, et al. Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med. 2009;47(6):724–744.
   PubMed Web of Science ®Google Scholar
• Griffiths WJ, Koal T, Wang Y, Kohl M, Enot DP, Deigner HP. Targeted metabolomics for biomarker discovery. Angew Chem Int Ed Engl. 2010;49(32):5426–5445.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Tzur D, Knox C, et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007;35(Database issue):D521–D526.
   PubMed Web of Science ®Google Scholar
• Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem. 2012;58(1):139–147.
   PubMed Web of Science ®Google Scholar
• Cho YE, Singh TS, Lee HC, et al. In-depth identification of pathways related to cisplatin-induced hepatotoxicity through an integrative method based on an informatics-assisted label-free protein quantitation and microarray gene expression approach. Mol Cell Proteomics. 2012;11(1):M111.010884.
   Web of Science ®Google Scholar
• Waters MD, Fostel JM. Toxicogenomics and systems toxicology: aims and prospects. Nat Rev Genet. 2004;5(12):936–948.
   PubMed Web of Science ®Google Scholar